Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  New England Journal of Medicine

• Publication date

  2009-12-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.1056/NEJMoa0805019PMID 19339720
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Global cancer statistics

  2011cited by this paper
• Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.

  2009cited by this paper
• KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab.

  2008cited by this paper
• Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.

  2008cited by this paper
• Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

  2008cited by this paper
• Correlation of KRAS status (wild type [wt] vs. mutant [mt]) with efficacy to first-line cetuximab in a study of cetuximab single agent followed by cetuximab + FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC)

  2008cited by this paper
• K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

  2008cited by this paper
• Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group.

  2008cited by this paper
• KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

  2008cited by this paper
• Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy

  2007cited by this paper
• Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.

  2007cited by this paper
• Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer.

  2007cited by this paper
• The multidisciplinary management of gastrointestinal cancer. The integration of cytotoxics and biologicals in the treatment of metastatic colorectal cancer.

  2007cited by this paper
• Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.

  2007cited by this paper
• 3004 ORAL Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) in the first-line treatment of metastastic colorectal cancer (mCRC): a large-scale phase II study, OPUS

  2007cited by this paper
• The integration of cytotoxics and biologicals in the treatment of metastatic colorectal cancer

  2007cited by this paper
• Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma.

  2006cited by this paper
• KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

  2006cited by this paper
• Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines.

  2006cited by this paper
• Global Cancer Statistics, 2002

  2005cited by this paper
• Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

  2004cited by this paper
• A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

  2004cited by this paper
• Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.

  2004cited by this paper
• FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.

  2004cited by this paper
• Rapid detection of K-ras mutations in bile by peptide nucleic acid-mediated PCR clamping and melting curve analysis: comparison with restriction fragment length polymorphism analysis.

  2004cited by this paper
• Cetuximab+FOLFIRI as first-line treatment for metastatic colorectal CA.

  2004cited by this paper
• Single nucleotide polymorphism genotyping using short, fluorescently labeled locked nucleic acid (LNA) probes and fluorescence polarization detection.

  2002cited by this paper
• End points in cancer clinical trials and the drug approval process.

  2002cited by this paper
• Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.

  2000cited by this paper
• Activation of c-K-ras mutations in human gastrointestinal tumors.

  2000cited by this paper
• Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.

  2000cited by this paper
• High frequency of K-ras mutations in sporadic colorectal adenomas.

  1993cited by this paper
• Statistical Methods for Rates and Proportions, 2nd ed

  1981cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper

• Impact of ECOG performance status 2 participants on outcomes of pivotal cancer clinical trials: a meta-analysis and meta-regression

  2026cites this paper
• Relationship between recurrent colorectal cancer and EGFR inhibitor-induced dermatological side effects: a focus on paronychia

  2026cites this paper
• Repurposing dronedarone for colorectal cancer therapeutic via suppression of the AKT/ERK signaling pathways.

  2026cites this paper
• Phenome-wide analysis of copy number variants in 470,727 UK Biobank genomes.

  2026cites this paper
• Chrysopogon zizanioides (Vetiver) Essential Oil from Qatar Targets AKT1 and STAT3 in Colorectal and Lung Cancer: GC-MS Profiling, In Vitro Antiproliferative Activity, and In Silico Analyses

  2026cites this paper
• Real-World Survival Outcomes Following Metastasectomy in RAS Wild-Type mCRC: Insights from a Multicentre National Cohort Study

  2026cites this paper
• Chemotherapy triggers immune evasion by fostering LEPR+ Kupffer cell differentiation in liver metastases.

  2026cites this paper
• Sensitive cell-free DNA assay for accurate detection of RAS and BRAF mutations in liquid biopsies of patients with metastatic colorectal cancer: Final results of the multicentric ColoBEAM study

  2025cites this paper
• Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2024 for the treatment of colorectal cancer

  2025cites this paper
• Gene expression profile in colon cancer therapeutic resistance and its relationship with the tumor microenvironment

  2025cites this paper
• Contemporary Tumor Histology Grouping for Survival Prediction of Patients With Metastatic Long-bone Disease Undergoing Surgery.

  2025cites this paper
• Anti‐epidermal growth factor receptor monoclonal antibody combined with chemotherapy in penile cancer: A prospective, multicenter, phase 1 study

  2025cites this paper
• Immunological landscape of colorectal cancer: tumor microenvironment, cellular players and immunotherapeutic opportunities

  2025cites this paper
• Liver Metastasis in Cancer: Molecular Mechanisms and Management

  2025cites this paper
• EMB‐01, a Tetravalent Bispecific Antibody, Inducing Co‐Degradation of EGFR and c‐Met for Enhanced Anti‐Tumor Efficacy

  2025cites this paper
• Expression of Bacillus in colorectal tissues is associated with improved cetuximab therapy for patients with metastatic colorectal cancer

  2025cites this paper
• High E2F7 Expression Indicates Pancreatic Cancer Aggressiveness and Downregulation of E2F7 Enhances Sensitivity to S-1.

  2025cites this paper
• Estrategia oncoquirúrgica para el manejo de las metástasis hepáticas de origen colorrectal

  2025cites this paper
• Immunotherapy for precision medicine in colorectal cancer

  2025cites this paper
• Revolutionizing cancer diagnosis with computational biology in the era of digital healthcare

  2025cites this paper
• Recent clinical advances in nonconjugated antibodies and antibody-drug conjugates for colorectal cancer treatment

  2025cites this paper
• Gastrointestinal cancer: molecular pathogenesis and targeted therapy

  2025cites this paper
• THSD7A as a novel prognostic factor for colorectal carcinoma

  2025cites this paper
• Hepatic Perfusion for Diffuse Metastatic Cancer to the Liver: Open and Percutaneous Techniques.

  2025cites this paper
• TRIM26 deficiency potentially suppresses colorectal cancer liver metastasis through NF-κB-mediated M1-like tumor-associated macrophage polarization

  2025cites this paper
• Immunotherapeutics in metastatic cancer management

  2025cites this paper
• The emerging role of Sotorasib plus Panitumumab combination therapy in colorectal cancer treatment

  2025cites this paper
• An exosome-based liquid biopsy predicts depth of response and survival outcomes to cetuximab and panitumumab in metastatic colorectal cancer: The EXONERATE Study.

  2025cites this paper
• Depth of response in patients with locally advanced pancreatic cancer treated with first-line chemotherapy: A supplementary analysis of JCOG1407.

  2025cites this paper
• Adverse Effects of Dupilumab in a Child with Atopic Dermatitis: A Case Report of Anaphylaxis and Literature Review

  2025cites this paper
• Black–White disparities across the colorectal cancer care continuum in the USA

  2025cites this paper
• Anticancer signal transduction pathways of selenium nanoparticles in mouse colorectal cancer model.

  2025cites this paper
• Characteristics of Patients and Prognostic Factors Across Treatment Lines in Metastatic Colorectal Cancer: An Analysis From the Aide et Recherche en Cancérologie Digestive Database

  2025cites this paper
• Overview of the Surgical Management of Liver Oligometastatic Disease in Colorectal Cancer

  2025influential citation
• Current Status of Precision Medicine in Colorectal Cancer in Japan

  2025cites this paper
• The current landscape of neoadjuvant therapy for resectable colon cancer

  2025cites this paper
• Synchronous metastases from colorectal cancer. Treatment and long-term survival compared to patients with metachronous metastases: a population-based study from Central Norway 2001–2015

  2025cites this paper
• In vitro 3D drug sensitivity testing for patient-derived tumor-like cell clusters and whole-exome sequencing to personalize postoperative treatment: A study protocol for a multicenter randomized controlled trial

  2025cites this paper
• Antibody treatments for digestive cancers: Past, present, and future.

  2025cites this paper
• Strategia oncochirurgica di gestione delle metastasi epatiche di origine colorettale

  2025cites this paper
• An anti-PD-1 antibody (SCT-I10A) plus anti-EGFR antibody (SCT200) and chemotherapy for RAS/BRAF wild-type metastatic colorectal cancer: A phase Ib study.

  2025cites this paper
• Current and emerging concepts for systemic treatment of metastatic colorectal cancer

  2025cites this paper
• Genetic, Epidemiological, Clinical, and Therapeutic Trajectories in Colon and Rectal Cancers

  2025cites this paper
• Hepatic arterial infusion is effective in patients with unresectable colorectal liver metastases refractory to standard systemic chemotherapy: A retrospective cohort study

  2025cites this paper
• A New Hope: Dual Human Epidermal Growth Factor Receptor 2 Blockade and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Amplified Colorectal Cancer – A Case Report and Literature Review

  2025cites this paper
• Harnessing epigenetics: Genome-wide DNA methylation assay for colorectal cancer therapy.

  2025cites this paper
• Search for Mutations Connected With Non‐Response to Anti‐EGFR Therapy in mCRC in the Morphologically Defined Regions of Primary Tumours

  2025cites this paper
• New depths: exploring the current landscape of colorectal cancer

  2025influential citation
• Surgical Management of Colorectal Cancer Liver Metastases.

  2025cites this paper
• Circulating tumor DNA in colorectal cancer: biology, methods and applications

  2025cites this paper
• Combination of 5‐Fluorouracil and Thymoquinone for Enhanced Cytotoxicity, Genotoxicity and Apoptosis In Colorectal Cancer: In Vitro and In Vivo Studies

  2025cites this paper
• WITHDRAWN: OncoStratifier: Stratifying Oncogene-addicted Cohorts By Drug Response

  2025cites this paper
• Multi-omics analysis reveals the role of tumor-infiltrating CD4+CCR7+ T cells in EGFR antibody resistance and prognosis of hepatocellular carcinoma

  2025cites this paper
• Molecular Profiling of KRAS, NRAS, and BRAF in Colorectal Cancer: Insights From a Libyan Cohort

  2025cites this paper
• Panitumumab versus cetuximab in combination with irinotecan in refractory metastatic colorectal cancer.

  2025cites this paper
• Targeting Ferroptosis in Gastrointestinal Tumors: Interplay of Iron-Dependent Cell Death and Autophagy.

  2025cites this paper
• KRAS, NRAS, and BRAF Hot-Spot Mutations in Relation to Sidedness of Primary Colorectal Cancer: A Retrospective Cohort Study

  2025cites this paper
• Digestive cancers: mechanisms, therapeutics and management

  2025cites this paper
• BRAF V600E and Non-V600E Mutations in RAS Wild-Type Metastatic Colorectal Cancer: Prognostic and Therapeutic Insights from a Nationwide, Multicenter, Observational Study (J-BROS)

  2025cites this paper
• Clinical usefulness of anti-α3Gal immunoglobulin E assays for cetuximab-mediated anaphylaxis in head and neck cancer

  2025cites this paper
• Pathogenetic development, diagnosis and clinical therapeutic approaches for liver metastasis from colorectal cancer (Review)

  2025cites this paper
• Real-World Evidence of Bevacizumab and Panitumumab Drug Resistance and Drug Ineffectiveness from EudraVigilance Database

  2025cites this paper
• Impact of trifluridine/tipiracil plus bevacizumab on tumor shrinkage and depth of response in refractory metastatic colorectal cancer: analysis of the SUNLIGHT trial.

  2025cites this paper
• Clinical Impact of Sub-Clonal RAS/BRAF Alterations in Liquid Biopsies From Patients With Advanced or Metastatic CRC.

  2025cites this paper
• KRAS Mutations in Cancer: From Molecular Insights to Therapeutic Strategies.

  2025cites this paper
• Decoding colorectal cancer targeted therapy: a bibliometric journey of the last decade (2015–2024)

  2025cites this paper
• Advances and challenges in cancer immunotherapy: Strategies for personalized treatment.

  2025cites this paper
• Proximity-induced membrane protein degradation for cancer therapies.

  2025cites this paper
• EGFR controls transcriptional and metabolic rewiring in KRASG12D colorectal cancer

  2025cites this paper
• First-line treatment of anti-EGFR monoclonal antibody cetuximab β plus FOLFIRI versus FOLFIRI alone in Chinese patients with RAS/BRAF wild-type metastatic colorectal cancer: a randomized, phase 3 trial

  2025cites this paper
• Outcomes of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC) and Liver-Directed Therapy for Synchronous Peritoneal and Liver Metastatic Colorectal Cancer: A Systematic Review with Meta-analysis

  2025cites this paper
• Longitudinal clinical, physiological and molecular profiling of female metastatic cancer patients: protocol and feasibility of a multicenter high-definition oncology study

  2025cites this paper
• Advancing targeted therapy for colorectal cancer: harnessing ligand-directed enzyme prodrug therapy for highly specific interventions

  2025cites this paper
• Clinical and prognostic characteristics of metastatic colorectal cancer with minor RAS mutations

  2025cites this paper
• Navigating beyond the surface - prognostic significance of KRAS, NRAS, BRAF, PIK3CA, and TP53 mutations examined by exons

  2025cites this paper
• Metastatic hepatic carcinoma: Mechanisms, emerging therapeutics, and future perspectives

  2025cites this paper
• Final Results of ERBIMOX: A Randomized Phase II Study of Modified FOLFOX7 With or Without Cetuximab as First-Line Treatment for KRAS Wild-type Metastatic Colorectal Cancer

  2025cites this paper
• Stratégie oncochirurgicale de prise en charge des métastases hépatiques d’origine colorectale

  2025cites this paper
• Liver metastasis of colorectal cancer: Mechanism and clinical therapy (Review)

  2025cites this paper
• Efficacy and safety of first-line cetuximab therapy for older patients (aged ≥ 70 years) with RAS wild-type metastatic colorectal cancer: a nationwide real-world study.

  2025cites this paper
• Clinical observation of combined transarterial chemoembolization and targeted therapy in postoperative recurrent colorectal cancer with liver metastasis

  2025cites this paper
• The RASAL2 variant promotes aberrant RAS signaling and resistance to anti-EGFR therapy in colorectal cancer

  2025cites this paper
• Nutritional Challenges in Older Cancer Patients: A Narrative Review of Assessment Tools and Management Strategies

  2025cites this paper
• A bibliometric analysis on KRAS, a targeted marker for blockbuster clinical drugs.

  2025cites this paper
• Molecular Targets in Metastatic Colorectal Cancer: A Review

  2025cites this paper
• First-line panitumumab, irinotecan, and trifluridine/tipiracil in patients with RAS wildtype metastatic colorectal cancer: PIT protocol

  2025cites this paper
• Factors Influencing the Duration of Maintenance Therapy in Metastatic Colorectal Cancer

  2024cites this paper
• Outcomes of upfront primary tumor resection in patients with synchronous RAS wild-type metastatic colorectal cancer.

  2024cites this paper
• Rational Design of an Epidermal Growth Factor Receptor Vaccine: Immunogenicity and Antitumor Research

  2024cites this paper
• Pharmacist intervention and identification of adverse events related to treatment efficacy in cancer chemotherapy to improve clinical outcomes

  2024cites this paper
• Pan-cancer analysis of NADPH oxidase 4 identifying its prognostic and immunotherapy predictive value and in vitro experimental verification in glioblastoma.

  2024cites this paper
• Progress on angiogenic and antiangiogenic agents in the tumor microenvironment

  2024cites this paper
• Sustained Endocytosis Inhibition via Locally‐Injected Drug‐Eluting Hydrogel Improves ADCC‐Mediated Antibody Therapy in Colorectal Cancer

  2024cites this paper
• Management of Metastatic Colorectal Cancer (mCRC): Real-World Recommendations

  2024cites this paper
• The efficacy of targeted therapy and/or immunotherapy with or without chemotherapy in patients with Colorectal Cancer: A Network Meta-Analysis.

  2024cites this paper
• Radiomics As Biomarkers for the Treatment of Non-small Cell Lung Cancer With Stereotactic Body Radiation Therapy: A Review of Concepts

  2024cites this paper
• Cetuximab-Induced Pneumonitis: An Overlooked Complication

  2024cites this paper
• Treatment Strategies’ Impact on Progression-Free Survival According to RMST Function in Metastatic Colorectal Cancer Patients: A Retrospective Study from Romania

  2024cites this paper
• Personalised medicine based on host genetics and microbiota applied to colorectal cancer.

  2024cites this paper
• NEOADJUVANT TREATMENT OF LIVER METASTASES OF COLORECTAL CANCER: PREDICTIVE FACTORS OF PATHOLOGICAL RESPONSE

  2024cites this paper